Novel Medications for Opiate Detoxification - 4

This study has been completed.
Sponsor:
Collaborators:
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT00000279
First received: September 20, 1999
Last updated: July 24, 2013
Last verified: December 2002
  Purpose

The purpose of this study is to evaluate novel medications for opiate detoxification.


Condition Intervention Phase
Opioid-Related Disorders
Substance-Related Disorders
Drug: Clonidine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Novel Medications for Opiate Detoxification

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Withdrawal severity

Estimated Enrollment: 0
Study Start Date: September 1994
Study Completion Date: August 1999
Primary Completion Date: August 1999 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000279

Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
VA Connecticut Healthcare System
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

No publications provided

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000279     History of Changes
Other Study ID Numbers: NIDA-09250-4, P50DA009250, P50-09250-4
Study First Received: September 20, 1999
Last Updated: July 24, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Clonidine
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics
Sensory System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on April 15, 2014